We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Delayed Early Genes Prevent Runaway Cell Division

By Biotechdaily staff writers
Posted on 05 Mar 2007
Cancer researchers have identified a cluster of genes in normal cells that prevent the type of runaway cell division that characterizes cancer cells.
When normal cells respond to the correct outside stimulus, such as binding of epidermal growth factor, to divide, a group of genes termed "immediate early genes” begin to function. More...
Immediate early genes (IEGs) are activated transiently and rapidly in response to a wide variety of cellular stimuli. They represent a standing response mechanism that is activated at the transcription level in the first round of response to stimuli, before any new proteins are synthesized. Thus, IEGs are distinct from "late response” genes, which can only be activated later following the synthesis of early response gene products.
In the current study, investigators at the Weizmann Institute of Science (Rehovot, Israel) identified a distinct subset of IEGs that they call "delayed” early genes. The task of these genes is to suppress IEG activity so that cell division stops and does not spin out of control.
Their study, published in the February 25, 2007, online edition of Nature Genetics, revealed that after being triggered by the proper stimulus, a first wave of IEGs initiated cell division and was active for from 20 to 40 minutes. After that, four more waves of genetic activity, ranging from 40 to 240 minutes after the signal, were comprised primarily of gene activity tied to the process of halting cell division. Overall, the investigators identified 50 genes that interfered with the activities of the first wave of genes. This inhibitory system functioned by producing proteins that directly attached to the cell-division genes, hindering their activity.

As might be anticipated, analysis of the activity of the delayed early genes in cancerous tissues showed that they did not function or functioned only poorly. This misbehavior was directly linked to the aggressiveness of the cancer and the likelihood of the patient to recover.


Related Links:
Weizmann Institute of Science

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Electrolyte Analyzer
BKE-B
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.